Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab, American Medical Association. It binds to KIR2DL1/2/3.
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
Clinical trials A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017.Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017
It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned.Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017
nine clinical trials of lirilumab are registered as active.lirilumab trials
References